1. A boundary acoustic wave device comprising:
a laminate including a plurality of boundary acoustic wave elements; wherein
each of the plurality of boundary acoustic wave elements includes a first solid layer made of a piezoelectric material, a second solid layer disposed on the first solid layer and made of one of a piezoelectric material and an insulating material, and a boundary acoustic wave exciting interdigital transducer disposed in a boundary between the first and second solid layers.
2. A boundary acoustic wave device according to claim 1, further comprising a surface acoustic wave element disposed on an external surface of the laminate, wherein the surface acoustic wave element includes a piezoelectric body and a surface acoustic wave exciting interdigital transducer disposed on one surface of the piezoelectric body.
3. A boundary acoustic wave device according to claim 1, further comprising an electrically conductive layer disposed at at least one of an external surface of the laminate, a boundary between adjacent boundary acoustic wave elements, and a location between one of the boundary acoustic wave elements and the external surface of the laminate.
4. A boundary acoustic wave device according to claim 1, further comprising an acoustic wave absorbing layer disposed at at least one of an external surface of the laminate, a boundary between adjacent boundary acoustic wave elements, and a location between one of the boundary acoustic wave elements and the external surface of the laminate.
5. A boundary acoustic wave device according to claim 1, further comprising a third solid layer having a different acoustic impedance from that of the first and second solid layers and disposed at at least one of an external surface of the laminate, a boundary between adjacent boundary acoustic wave elements, and a location between one of the boundary acoustic wave elements and the external surface of the laminate.
6. A boundary acoustic wave device according to claim 2, wherein a boundary between the solid layers, other than the boundary having the boundary acoustic wave exciting interdigital transducer, is not flatter than the surface having the surface acoustic wave exciting interdigital transducer.
7. A boundary acoustic wave device according to claim 1, wherein a location of the boundary acoustic wave exciting interdigital transducer disposed on one boundary acoustic wave element is shifted in a laminating direction from a location of the boundary acoustic wave exciting interdigital transducer disposed on another boundary acoustic wave element.
8. A boundary acoustic wave device according to claim 1, further comprising an inductance element connected between the boundary acoustic wave exciting interdigital transducers of different boundary acoustic wave elements.
9. A boundary acoustic wave device according to claim 1, further comprising at least two boundary acoustic wave elements electrically connected to each other via a through-hole electrode provided in the laminate, wherein an elastic material is provided inside the through-hole electrode.
10. A boundary acoustic wave device according to claim 1, further comprising:
at least two boundary acoustic wave elements electrically connected to each other via a through-hole electrode arranged in the laminate; wherein
the through-hole electrode includes a plurality of through-hole electrode sections including upper and lower through-hole electrode sections arranged at different locations in a plane at a height within the laminate, and the two through-hole electrode sections are electrically connected to each other through an electrical connection junction extending in the plane.
11. A boundary acoustic wave device according to claim 1, wherein at least two boundary acoustic wave elements are electrically connected to each other via a wiring electrode arranged on an external surface of the laminate.
12. A boundary acoustic wave device according to claim 11, wherein a step is provided on the external surface of the laminate, and the wiring electrode is arranged on the step.
13. A boundary acoustic wave device according to claim 1, further comprising a temperature characteristic improving layer disposed at at least one of an external surface of the laminate, a boundary between adjacent boundary acoustic wave elements, and a location between one of the boundary acoustic wave elements and the external surface of the laminate; wherein
the temperature characteristic improving layer has a linear expansion coefficient in a direction that is substantially parallel with the boundary plane of the boundary acoustic wave element having the boundary acoustic wave exciting interdigital transducer therein that is less than a linear expansion coefficient of the first and second solid layers, or has a linear expansion coefficient that is different from the linear expansion coefficient of the first and second solid layers in polarity.
14. A boundary acoustic wave device according to claim 1, further comprising:
a high thermal conductivity layer, disposed at at least one of an external surface of the laminate, a boundary between adjacent boundary acoustic wave elements, and a location between one of the boundary acoustic wave elements and the external surface of the laminate; wherein
the high thermal conductivity layer has a higher thermal conductivity than an adjacent boundary acoustic wave element.
15. A boundary acoustic wave device according to claim 1, wherein the boundary acoustic wave elements are bonded together by a cavity forming member such that a cavity is provided in at least one boundary between the boundary acoustic wave elements.
16. A boundary acoustic wave device according to claim 1, further comprising a circuit element disposed at at least one of an external surface of the laminate, a boundary between adjacent boundary acoustic wave elements, and a location between one of the boundary acoustic wave elements and the external surface of the laminate.
17. A boundary acoustic wave device according to claim 1, further comprising a base substrate which defines a stress relaxation body and on which the laminate is mounted.
18. A boundary acoustic wave device according to claim 17, wherein the base substrate is made of a material that is harder than the first and second solid layers of the boundary acoustic wave element.
19. A boundary acoustic wave device according to claim 1, wherein the thickness of each of the first and second solid layers is substantially equal to or greater than \u03bb, where \u03bb is the wavelength of a boundary acoustic wave.
20. A method for manufacturing a boundary acoustic wave device, the method comprising steps of:
manufacturing a boundary acoustic wave element by laminating a first solid layer made of a piezoelectric material and a second solid layer made of one of a piezoelectric material and an insulating material, with a boundary acoustic wave exciting interdigital transducer being interposed therebetween;
repeating the step of manufacturing the boundary acoustic wave element to produce a plurality of boundary acoustic wave elements; and
producing a laminate by laminating the plurality of boundary acoustic wave elements.
21. A method according to claim 20, further comprising steps of:
disposing an acoustic wave absorbing layer at at least one of an external surface of the laminate, a boundary between adjacent boundary acoustic wave elements, and a location between one of the boundary acoustic wave elements and the external surface of the laminate; and
degassing a gas in the acoustic wave absorbing layer when the first and second solid layers are bonded together with the acoustic wave absorbing layer and the boundary acoustic wave exciting interdigital transducer interposed therebetween.
22. A boundary acoustic wave device comprising:
a first solid layer made of a piezoelectric material;
a second solid layer disposed on the first solid layer and made of one of a piezoelectric material and an insulating material;
a boundary acoustic wave exciting interdigital transducer arranged at a boundary between the first and second solid layers; and
a surface acoustic wave exciting interdigital transducer disposed on the surface of the first solid layer.
23. A boundary acoustic wave device according to claim 22, further comprising a surface acoustic wave element disposed on an external surface of the laminate, wherein the surface acoustic wave element includes a piezoelectric body and a surface acoustic wave exciting interdigital transducer disposed on one surface of the piezoelectric body.
24. A boundary acoustic wave device according to claim 22, further comprising an electrically conductive layer disposed at at least one of an external surface of the laminate, a boundary between adjacent boundary acoustic wave elements, and a location between one of the boundary acoustic wave elements and the external surface of the laminate.
25. A boundary acoustic wave device according to claim 22, further comprising an acoustic wave absorbing layer disposed at at least one of an external surface of the laminate, a boundary between adjacent boundary acoustic wave elements, and a location between one of the boundary acoustic wave elements and the external surface of the laminate.
26. A boundary acoustic wave device according to claim 22, further comprising a third solid layer having a different acoustic impedance from that of the first and second solid layers and disposed at at least one of an external surface of the laminate, a boundary between adjacent boundary acoustic wave elements, and a location between one of the boundary acoustic wave elements and the external surface of the laminate.
27. A boundary acoustic wave device according to claim 23, wherein a boundary between the solid layers, other than the boundary having the boundary acoustic wave exciting interdigital transducer, is not flatter than the surface having the surface acoustic wave exciting interdigital transducer.
28. A boundary acoustic wave device according to claim 22, wherein a location of the boundary acoustic wave exciting interdigital transducer disposed on one boundary acoustic wave element is shifted in a laminating direction from a location of the boundary acoustic wave exciting interdigital transducer disposed on another boundary acoustic wave element.
29. A boundary acoustic wave device according to claim 22, further comprising an inductance element connected between the boundary acoustic wave exciting interdigital transducers of different boundary acoustic wave elements.
30. A boundary acoustic wave device according to claim 22, further comprising at least two boundary acoustic wave elements electrically connected to each other via a through-hole electrode provided in the laminate, wherein an elastic material is provided inside the through-hole electrode.
31. A boundary acoustic wave device according to claim 22, further comprising:
at least two boundary acoustic wave elements electrically connected to each other via a through-hole electrode arranged in the laminate; wherein
the through-hole electrode includes a plurality of through-hole electrode sections including upper and lower through-hole electrode sections that are arranged at different locations in a plane at a height within the laminate, and the two through-hole electrode sections are electrically connected to each other through an electrical connection junction extending in the plane.
32. A boundary acoustic wave device according to claim 22, wherein at least two boundary acoustic wave elements are electrically connected to each other via a wiring electrode arranged on an external surface of the laminate.
33. A boundary acoustic wave device according to claim 32, wherein a step is provided on the external surface of the laminate, and the wiring electrode is arranged on the step.
34. A boundary acoustic wave device according to claim 22, further comprising a temperature characteristic improving layer disposed at at least one of an external surface of the laminate, a boundary between adjacent boundary acoustic wave elements, and a location between one of the boundary acoustic wave elements and the external surface of the laminate; wherein
the temperature characteristic improving layer has one of a linear expansion coefficient in a direction that is substantially parallel with the boundary plane of the boundary acoustic wave element having the boundary acoustic wave exciting interdigital transducer therein less than a linear expansion coefficient of the first and second solid layers forming the boundary acoustic wave element, and a linear expansion coefficient that is different from the linear expansion coefficient of the first and second solid layers in polarity.
35. A boundary acoustic wave device according to claim 22, further comprising:
a high thermal conductivity layer, disposed at at least one of an external surface of the laminate, a boundary between adjacent boundary acoustic wave elements, and a location between one of the boundary acoustic wave elements and the external surface of the laminate; wherein
the high thermal conductivity layer has a higher thermal conductivity than an adjacent boundary acoustic wave element.
36. A boundary acoustic wave device according to claim 22, wherein the boundary acoustic wave elements are bonded together by a cavity forming member such that a cavity is provided in at least one boundary between the boundary acoustic wave elements.
37. A boundary acoustic wave device according to claim 22, further comprising a circuit element disposed at at least one of an external surface of the laminate, a boundary between adjacent boundary acoustic wave elements, and a location between one of the boundary acoustic wave elements and the external surface of the laminate.
38. A boundary acoustic wave device according to claim 22, further comprising a base substrate which defines a stress relaxation body and on which the laminate is mounted.
39. A boundary acoustic wave device according to claim 38, wherein the base substrate is made of a material that is harder than the first and second solid layers of the boundary acoustic wave element.
40. A boundary acoustic wave device according to claim 22, wherein the thickness of each of the first and second solid layers is substantially equal to or greater than \u03bb, where \u03bb is the wavelength of a boundary acoustic wave.
41. A method for manufacturing a boundary acoustic wave device, the method comprising steps of:
manufacturing a boundary acoustic wave element by laminating a first solid layer made of a piezoelectric material and a second solid layer made of one of a piezoelectric material and an insulating material, with a boundary acoustic wave exciting interdigital transducer interposed therebetween and a surface acoustic wave exciting interdigital transducer disposed on the surface of the first solid layer;
repeating the step of manufacturing the boundary acoustic wave element to produce a plurality of boundary acoustic wave elements; and
producing a laminate by laminating the plurality of boundary acoustic wave elements.
42. A method according to claim 41, further comprising the steps of:
disposing an acoustic wave absorbing layer at at least one of an external surface of the laminate, a boundary between adjacent boundary acoustic wave elements, and a location between one of the boundary acoustic wave elements and the external surface of the laminate; and
degassing a gas in the acoustic wave absorbing layer when the first and second solid layers are bonded together with the acoustic wave absorbing layer and the boundary acoustic wave exciting interdigital transducer interposed therebetween.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
What is claimed is:
1. A novel compound of formula (I):
15
or stereoisomers thereof, N-Oxides thereof, pharmaceutically acceptable salts thereof, and prodrugs thereof, wherein:
R is independently at each occurrence selected from the group: H, NR1R2, NR1C(O)R3, NR1C(O)OR5, NHC(O)NR1R2, NHC(S)NR1R2, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from 0, N, and S, wherein the heterocycle is substituted with 0-4 R4 substituents;
R1 is selected from the group: H, halo, CN, C1-4 haloalkyl, C1-4 alkyl, phenyl, and benzyl;
R2 is selected from the group: H, C1-4 alkyl, phenyl, and benzyl;
alternatively, R1 and R2, together with the nitrogen atom to which they are attached, form a 4-8 membered heterocycl group or a 4-8 membered heterocyclenyl group containing an additional 0-1 N, S, or O atom, wherein the heterocycl or heterocyclenyl group is substituted with 0-4 R4 substituents;
R3 is selected from the group: H, halo, CN, C1-4 haloalkyl, C1-4 alkyl, phenyl, and benzyl; and
R4 is selected from the group: halo, CN, C1-4 haloalkyl, C1-4 alkyl, phenyl, and benzyl.
R5 is selected from the group: H, C1-4 alkyl, phenyl, and benzyl.
2. A compound according to claim 1, wherein:
R is a 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is substituted with 0-3 R4 substituents.
3. A compound according to claim 1, wherein:
R is a 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is substituted with 0-2 R4 substituents.
4. A compound according to claim 1, wherein:
R is a 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is substituted with a R4 substituent.
5. A compound according to claim 1, wherein:
R is a 5-6 membered hetroaryl, heterocyclyl, or heterocyclenyl group, substituted with 0-3 R4 substituents.
6. A compound according to claim 1, wherein:
R is H or NR1R2;
R1 is selected from the group: H, C1-4 alkyl, phenyl, and benzyl;
R2 is selected from the group: H, C1-4 alkyl, phenyl, and benzyl;
alternatively, R1 and R2, together with the nitrogen atom to which they are attached, form a 4-8 membered heterocycl group or a 4-8 membered heterocyclenyl group containing an additional 0-1 N, S, or O atom, wherein the heterocycl or heterocyclenyl group is substituted with 0-3 R4 substituents; and
R4 is selected from the group:, halo, CN, C1-4 haloalkyl, C1-4 alkyl, phenyl, and benzyl.
7. A compound according to claim 1, wherein:
R is H or NR1R2;
R1 is selected from the group: H, C1-4 alkyl, phenyl, and benzyl; and
R2 is selected from the group: H, C1-4 alkyl, phenyl, and benzyl.
8. A compound according to claim 1, wherein:
R is H or NR1R2;
R1 and R2, together with the nitrogen atom to which they are attached, form a 4-8 membered heterocycl group containing an additional 0-1 N, S, or O atom, wherein the heterocycl is substituted with 0-3 R4 substituents; and
R4 is selected from the group:, halo, CN, C1-4 haloalkyl, C1-4 alkyl, phenyl, and benzyl.
9. A compound according to claim 1, wherein:
R is H or NR1R2;
R1 and R2, together with the nitrogen atom to which they are attached, form a 4-8 membered heterocyclyl group containing an additional 0-1 N, S, or O atom, wherein the heterocyclyl is substituted with 0-2 R4 substituents; and
R4 is selected from the group:, halo, CN, C1-4 haloalkyl, C1-4 alkyl, phenyl, and benzyl.
10. A compound according to claim 1, wherein:
R1 and R2, together with the nitrogen atom to which they are attached, form a heterocyclyl group selected from the group consiting of pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, and piperazinyl, wherein the heterocyclyl is substituted with 0-3 R4 substituents; and
R4 is selected from the group:, halo, CN, C1-4 haloalkyl, Cl-4 alkyl, phenyl, and benzyl.
11. A compound according to claim 1, wherein:
R1 and R2, together with the nitrogen atom to which they are attached, form a heterocyclyl group selected from the group consiting of piperidinyl, morpholinyl, and piperazinyl, wherein the heterocyclyl is substituted with 0-3 R4 substituents; and
R4 is selected from the group:, halo, CN, C1-4 haloalkyl, C1-4 alkyl, phenyl, and benzyl.
12. A compound according to claim 1, wherein:
R is H or NR1R2;
R1 and R2, together with the nitrogen atom to which they are attached, form a 4-8 membered heterocyclenyl group containing an additional 0-1 N, S, or O atom, wherein the heterocyclenyl is substituted with 0-3 R4 substituents; and R4 is selected from the group:, halo, CN, C1-4 haloalkyl, C1-4 alkyl, phenyl, and benzyl.
13. A compound according to claim 1, wherein:
R is H or NR1R2;
R1 and R2, together with the nitrogen atom to which they are attached, form a 4-8 membered heterocyclenyl group containing an additional 0-1 N, S, or O atom, wherein the heterocyclenyl is substituted with 0-2 R4 substituents; and
R4 is selected from the group:, halo, CN, C1-4 haloalkyl, C1-4 alkyl, phenyl, and benzyl.
14. A compound according to claim 1, wherein:
R is H or NR1R2;
R1 and R2, together with the nitrogen atom to which they are attached, form a 4-8 membered heterocyclenyl group selected from the group consisting of: 2-pyrrolinyl, 3-pyrrolinyl, 2-imidazolinyl, 2-pyrazolinyl, 1,2,3,4-tetrahydrohydropyridine, 1,2-dihydropyridyl, 1,4-dihydropyridyl, 1,2,3,6-tetrahydropyridine, 1,4,5,6-tetrahydropyrimidine,wherein the heterocyclenyl is substituted with 0-2 R4 substituents; and
R4 is selected from the group:, halo, CN, Cl-4 haloalkyl, C1-4 alkyl, phenyl, and benzyl.
15. A compound according to claim 1, wherein:
R4 is selected from the group: C1-4 haloalkyl, C1-4 alkyl, and benzyl.
16. A compound according to claim 1, wherein:
R is C1-4 alkyl.
17. A compound according to claim 1, wherein:
R4 is methyl.
18. A compound according to claim 1, wherein:
R is NR1R2; and
R1 and R2, together with the nitrogen atom to which they are attached, form a 4-8 membered heterocyclyl group containing an additional 0-1 N, S, or O atom, wherein the heterocyclyl is substituted with a R4 substituent.
19. A compound according to claim 1, wherein:
R is NR1R2; and
R1 and R2, together with the nitrogen atom to which they are attached, form a 4-8 membered heterocyclenyl group containing an additional 0-1 N, S, or O atom, wherein the heterocyclenyl is substituted with a R4 substituent.
20. A compound according to claim 1, wherein:
3-(2,4-dimethylthiazol-5-yl)-5-(carbamoylamino)indeno1,2-cpyrazol-4-one;
3-(2,4-dimethylthiazol-5-yl)-5-(morpholinocarbamoylamino)indeno1,2-cpyrazol-4-one;
3-(2,4-dimethylthiazol-5-yl)-5-((1-methyl-1-phenylamino)carbamoylamino)indeno1,2-cpyrazol-4-one;
3-(2,4-dimethylthiazol-5-yl)-5-((2,6-dimethylpiperidino)carbamoylamino)indeno1,2-cpyrazol-4-one; and
3-(2,4-dimethylthiazol-5-yl)-5-((4-methylpiperazino)carbamoylamino)indeno1,2-cpyrazol-4-one;
or stereoisomers thereof, N-Oxides thereof, pharmaceutically acceptable salts thereof, and prodrugs thereof.
21. A pharmaceutical composition comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1.
22. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier, a compound according to claim 1 or a pharmaceutically acceptable salt or prodrug form thereof, and a cytostatic or cytotoxic agent.
23. A method of treating a cell proliferative disease associated with CDK activity in a patient in need thereof, comprising administrering to said patient a pharmaceutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof, wherein the proliferative diseases is selected from the group consisting of: Alzheimer’s disease, viral infections, auto-immune diseases, fungal disease, cancer, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis, neurodegenerative disorders and post-surgical stenosis and restenosis.
24. A method of treating cancer associated with CDK activity in a patient in need thereof,comprising administrering to said patient a pharmaceutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof, wherein the cancer is selected from the group consisting of: carcinoma such as bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, hairy cell lymphoma and Burkett’s lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma and schwannomas; other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi’s sarcoma.
25. A method of treating a disease associated with apoptosis in a patient in need thereof, comprising administrering to said patient a pharmaceutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof, wherein the disease associated with apoptosis is selected from the group consisting of: cancer, viral infections, autoimmune diseases and neurodegenerative disorder.
26. A method of inhibiting tumor angiogenesis and metastasis in a patient in need thereof, comprising administrering to said patient a pharmaceutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.
27. A method of modulating the level of cellular RNA and DNA synthesis in a patient in need thereof, comprising administering to said patient a CDK inhibitory effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.
28. A method of treating viral infections in a patient in need thereof, comprising administering to said patient a CDK inhibitory effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof, wherein the viral infections is selected from the group consiting of HIV, hepatitis, human papilloma virus, herpesvirus, poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus.
29. A method of chemopreventing cancer in a patient, comprising administering to said patient in need thereof, a CDK inhibitory effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.
30. A method of inhibiting CDK activity comprising combining an effective amount of a compound according to claim 1, with a composition containing CDK.
31. A method of treating cancer associated with CDK activity in a patient in need thereof, comprising administrering to said patient a pharmaceutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof, in combination (administered together or sequentially) with known anti-cancer treatments such as radiation therapy or with cytostatic or cytotoxic agents, wherein such agents are selected from the group consisting of: DNA interactive agents, such as cisplatin or doxorubicin; topoisomerase II inhibitors, such as etoposide; topoisomerase I inhibitors such as CPT-11 or topotecan; tubulin interacting agents, such as paclitaxel, docetaxel or the epothilones; hormonal agents, such as tamoxifen; thymidilate synthase inhibitors, such as 5-fluorouracil; and anti-metabolites, such as methoxtrexate.
32. A method treating cell proliferative diseases associated with CDK activity in a patient in need thereof, comprising administrering to said patient a pharmaceutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof, in combination (administered together or sequentially) with known anti-proliferating agents selected from the group consisting of:, altretamine, busulfan, chlorambucil, cyclophosphamide, ifosfamide, mechlorethamine, melphalan, thiotepa, cladribine, fluorouracil, floxuridine, gemcitabine, thioguanine, pentostatin, methotrexate, 6-mercaptopurine, cytarabine, carmustine, lomustine, streptozotocin, carboplatin, cisplatin, oxaliplatin, iproplatin, tetraplatin, lobaplatin, JM216, JM335, fludarabine, aminoglutethimide, flutamide, goserelin, leuprolide, megestrol acetate, cyproterone acetate, tamoxifen, anastrozole, bicalutamide, dexamethasone, diethylstilbestrol, prednisone, bleomycin, dactinomycin, daunorubicin, doxirubicin, idarubicin, mitoxantrone, losoxantrone, mitomycin-c, plicamycin, paclitaxel, docetaxel, CPT-11, epothilones , topotecan, irinotecan, 9-amino camptothecan, 9-nitro camptothecan, GS-211, etoposide, teniposide, vinblastine, vincristine, vinorelbine, procarbazine, asparaginase, pegaspargase, methoxtrexate, octreotide, estramustine, and hydroxyurea.
33. A method of inhibiting CDK1 activity, comprising adminsitering to a patient in need thereof an efective CDK1 inhibitory amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.
34. A method of inhibiting CDK2 activity, comprising adminsitering to a patient in need thereof an efective CDK2 inhibitory amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.
35. A method of inhibiting CDK3 activity, comprising adminsitering to a patient in need thereof an efective CDK3 inhibitory amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.
36. A method of inhibiting CDK4 activity, comprising adminsitering to a patient in need thereof an efective CDK4 inhibitory amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.
37. A method of inhibiting CDK5 activity, comprising adminsitering to a patient in need thereof an efective CDK5 inhibitory amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.
38. A method of inhibiting CDK6 activity, comprising adminsitering to a patient in need thereof an efective CDK6 inhibitory amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.
39. A method of inhibiting CDK7 activity, comprising adminsitering to a patient in need thereof an efective CDK7 inhibitory amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.
40. A method of inhibiting CDK8 activity, comprising adminsitering to a patient in need thereof, an efective CDK8 inhibitory amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.
41. A method of inhibiting CDK9 activity, comprising adminsitering to a patient in need thereof an efective CDK9 inhibitory amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.
42. A pharmaceutical kit for treating a cell proliferative disease associated with CDK activity, said kit comprising a plurality of separate containers, wherein at least one of said containers contains a compound accordig to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof, and at least another of said containers contains one or more compounds selected from the group consisting of cytostatic or cytotoxic agents, such as for example, but not limited to, DNA interactive agents, such as carboplatin, cisplatin or doxorubicin; topoisomerase II inhibitors, such as etoposide; topoisomerase I inhibitors such as CPT-11 or topotecan; tubulin interacting agents, such as paclitaxel, taxane, docetaxel or the epothilones; hormonal agents, such as tamoxifen; thymidilate synthase inhibitors, such as 5-fluorouracil; and anti-metabolites, such as methoxtrexate, and said containers optionally contain a pharmaceutical carrier, which kit may be effectively utilized for carrying out combination therapies according to the invention.
43. A method of treating a patient having a disorder associated with excessive cell proliferation, comprising administering to the patient a therapeutically effective amount of a compound of claim 1, such that the excessive cell proliferation in the patient is reduced.
44. An enhanced method of inhibiting CDK activity, comprising adminsitering to a patient in need thereof an efective CDK inhibitory amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.